Draft CFDA Guidance on Drug Data Management Practices

Posted 31 October 2016 By Yingying Liu, Siegfried Schmitt

placeholder+image The China Food and Drug Administration (CFDA) has recently issued a new draft guidance document on data integrity, covering the entire data lifecycle from R&D to commercial production and distribution. This article is a translation of the summary of the draft guidance.

Share this article:

Categories: Clinical, Manufacturing, Preclinical, Research and development, News, China, CFDA

Tags: Data Management

Regulatory Exchange: Latest Updates From the Community